menu

CME: Anticoagulation in CAD and PAD: Translating Data into Practice

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Anticoagulation in CAD and PAD: Translating Data into Practice

Anticoagulation in CAD and PAD: Translating Data into Practice
RestartResume
What do COMPASS and other anticoagulation clinical trials tell us about treating polyvascular disease? A panel of experts shares the findings.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This innovative, 30-minute, case-based CME activity provides an opportunity for participants to evaluate the clinical issues and recent data regarding anticoagulation in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). The program covers challenges faced by healthcare providers in caring for patients with polyvascular disease. Topics include:

    • COMPASS: Putting Data into Perspective
    • COMMANDER: Anticoagulation in Patients with HF and CAD
    • MARINER: Anticoagulation Data
  • Provider(s)/Educational Partner(s)

    Jointly provided by the Annenberg Center for Health Sciences at Eisenhower (www.annenberg.net) and Medtelligence in collaboration with Postgraduate Institute for Medicine.

  • Commercial Support

    This activity is supported by an independent medical educational grant from Janssen Scientific Affairs, LLC.

  • Target Audience

    This activity has been designed to meet the educational needs of Cardiologists, Interventionalists, Internists, NPs, PAs, and other allied healthcare professionals involved in the care of patients with polyvascular disease.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
    • Relate the clinical implications of anticoagulation in CAD based on recent data
    • Utilize NOACs at the proper dose for patients with moderate or high risk of stroke, advising patients of the risks and benefits, and performing proper follow-up
    • Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended
    • Use anticoagulant strategies as thromboprophylaxis to treat medically ill patients discharged from the hospital 
  • Faculty

    Jeffrey Weitz, MD, Chair
    Professor of Medicine & Biochemistry and Biomedical Sciences
    McMaster University
    Executive Director
    Thrombosis & Atherosclerosis Research Institute
    Hamilton, ON, Canada

    Roxana Mehran, MD, Co-Chair
    Professor of Medicine (Cardiology) and Population Health Science and Policy
    Director of Interventional Cardiovascular Research and Clinical Trials
    Zena and Michael A. Weiner Cardiovascular Institute
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Manesh R. Patel, MD
    Professor of Medicine
    Chief, Division of Cardiology
    Co-Director, Heart Center
    Duke University Health System
    Durham, NC

    Alex C. Spyropoulos, MD
    Professor of Medicine
    The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
    Professor, Center for Health Innovations and Outcomes Research
    The Feinstein Institute for Medical Research
    System Director, Anticoagulation and Clinical Thrombosis Services
    Northwell Health
    New York, NY

    Faiez Zannad, MD, PhD
    Professor of Therapeutics and Cardiology
    Head, Division of Heart Failure, Hypertension and Preventive Cardiology
    Department of Cardiovascular Disease
    Université de Lorraine
    Director, INSERM Clinical Investigation Center
    Nancy, France

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Roxana Mehran, MD: Consulting Fees (Institution): Abbott, Spectranetics; Consulting Fees (Dr. Mehran): Boston Scientific, Cardiovascular Systems, Siemens, Medscape; Consulting Fees (Spouse): The Medicines Company, Abiomed; Contracted Research: AstraZeneca, Bayer, Beth Israel Deaconess, BMS, CSL Behring, Eli Lilly/DSI, Medtronic, Novartis, OrbusNeich; Ownership Interest: Claret Medical, Elixir Medical; Other: DSMB-Watermark Research Partners, Exec. Committee-Janssen and Osprey Medical.
    • Manesh R. Patel, MD: Consulting Fees: Bayer, Janssen, AstraZeneca.
    • Alex C. Spyropoulos, MD: Consulting Fees: Bayer, Janssen, Boehringer Ingelheim, Portola; Contracted Research: Janssen, Boehringer Ingelheim.
    • Jeffrey Weitz, MD: Consulting Fees: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, Portola.
    • Faiez Zannad, MD, PhD: Consulting Fees: Janssen, Bayer.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The PIM planners and managers have nothing to report.

    Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

    The Medtelligence planners and managers have nothing to disclose.

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period November 15, 2018, through November 15, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity and evaluation will have a statement of credit made available immediately.

    If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.